A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of early intervention (dosing within 2 hours of onset of the
migraine attack) with eletriptan 40mg on mild versus moderate to severe pain intensity of
migraine.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.